<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148002</url>
  </required_header>
  <id_info>
    <org_study_id>PDBowel2017</org_study_id>
    <nct_id>NCT03148002</nct_id>
  </id_info>
  <brief_title>Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation</brief_title>
  <official_title>An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaclyn Tran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Constipation is a common condition, which occurs one in four Canadians. Maintaining regular
      bowel movements is imperative because constipation can affect the quality of PD dialysate
      flow and result in an unwanted effect on the dialysis adequacy.

      There is limited data on how to best manage constipation in the peritoneal dialysis
      population. Polyethylene glycol (PEG) is an osmotic laxative that is becoming popular for
      prevention and treatment of constipation across Canada. Although some PD programs in Canada
      have already converted to PEG for management of constipation, more research in this
      population would help guide practice. For now, the current PD bowel regimen at the Nova
      Scotia Health Authority (NSHA) includes daily preventative therapy using a stimulant
      laxative, senna, along with an osmotic laxative, lactulose, for acute constipation.

      The investigators will review all patients in the NSHA PD program who have regular or recent
      laxative use for participation in this study. Patients included in this study will be
      randomly assigned to the Current Bowel Protocol or the PEG Bowel Protocol for 8 weeks.

      The goal is to determine if the PEG Bowel Protocol is as effective and safe for the
      prevention of constipation as the Current Bowel Protocol used in the PD Program. The
      investigators will use bowel function diaries and patient surveys to determine efficacy and
      safety outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Constipation is a common condition, which impacts one in four Canadians Maintaining regular
      bowel movements is important in the peritoneal dialysis (PD) population because constipation
      can negatively impact the quality of dialysate flow and can result in impaired dialysis
      adequacy. Unfortunately, treating constipation is challenging in PD patients because of the
      diet and fluid restrictions required in this population, as well as the need for constipating
      calcium based phosphate binders.

      Constipation treatment can be administered orally or rectally. Although patients often prefer
      oral therapy, there are occasions when rectal therapy is preferred (ie. rectal suppositories
      and enemas). Oral laxatives include bulk, osmotic, stimulant, and lubricants.

      In the Nova Scotia (NS) PD Program, patients are counseled to maintain a type 3-4 stool on
      the Bristol Stool Chart (BSC). An ideal stool is a type 4, which appears like a sausage or
      snake and is smooth and soft in consistency. To maintain a type 3-4 stool, current therapy
      includes senna 8.6-17.2 g twice daily with the addition of lactulose 30-60 mL twice daily, as
      needed. Rescue therapy in the Current Bowel Protocol is lactulose 30-60 mL every hour until
      bowel movement.

      There is limited evidence to guide the ideal bowel regimen in PD patients. Reasons to
      consider PEG therapy include the evidence promoting PEG in the general population with
      constipation, the positive outcomes found in a small population of PD patients (Mimidis
      2005), as well as positive feedback from other provinces who currently recommend PEG in PD
      patients. The investigators postulate the PEG protocol would be as effective and safe as the
      Current Bowel Protocol, and thus will evaluate PEG in the PD population, the investigators
      will conduct a prospective, interventional, randomized, open label, pilot study.

      All patients with recent laxative use will be approached for inclusion. Patients will be
      randomly assigned to the Current Bowel Protocol (senna/lactulose) or the PEG Bowel Protocol
      (PEG/lactulose) for 8 weeks.

      The primary objective is to compare the efficacy of the PEG Bowel Protocol in preventing
      constipation to the Current Bowel Protocol. We will review the safety of the regimens by
      monitoring for adverse events from all laxatives and explore the impact of constipation in
      patients who experience PD treatment failure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to received the Current Bowel Protocol or the PEG Bowel Protocol</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of constipation treatment success</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Successful treatment of constipation will be defined based on a modified ROME criteria developed by Dipalma 2007: relief of constipation for more than 50% of the weeks in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with laxative related adverse effects.</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Compare the occurrence of side effects during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline on the PAC-SYM questionnaire</measure>
    <time_frame>8 weeks.</time_frame>
    <description>Measure of the impact of constipation disease severity. PAC-SYM = Patient Assessment of Constipation Symptoms (Frank 1999 and Bove 2012)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline on the PAC-QOL questionnaire</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measure the impact of constipation on quality of life. PAC-QOL = Patient Assessment of Constipation Quality of Life (Marquis 2005 and Bove 2012)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peritoneal dialysis treatment failure requiring intervention</measure>
    <time_frame>8 weeks</time_frame>
    <description>Interventions include antibiotics for peritonitis, catheter re-positioning.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Constipation</condition>
  <condition>Peritoneal Dialysis Complication</condition>
  <arm_group>
    <arm_group_label>Current Bowel Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG Bowel Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Current Bowel Protocol (senna/lactulose)</intervention_name>
    <description>Stimulant and Osmotic Laxatives.</description>
    <arm_group_label>Current Bowel Protocol</arm_group_label>
    <other_name>Senna</other_name>
    <other_name>Lactulose</other_name>
    <other_name>Sennosides</other_name>
    <other_name>DIN 02242814</other_name>
    <other_name>DIN: 02412268</other_name>
    <other_name>NPN: 00367729</other_name>
    <other_name>NPN: 00026158</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG Bowel Protocol (PEG/lactulose)</intervention_name>
    <description>Osmotic Laxatives.</description>
    <arm_group_label>PEG Bowel Protocol</arm_group_label>
    <other_name>PEG</other_name>
    <other_name>Lax-A-Day</other_name>
    <other_name>Pegalax</other_name>
    <other_name>DIN: 02328232</other_name>
    <other_name>Restoralax</other_name>
    <other_name>DIN: 02318164</other_name>
    <other_name>DIN: 02317680</other_name>
    <other_name>Lactulose</other_name>
    <other_name>DIN 02242814</other_name>
    <other_name>DIN: 02412268</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients in the peritoneal dialysis program in Nova Scotia who are currently
             taking laxatives.

        Exclusion Criteria:

          -  Allergy or intolerance to any of the study laxatives (PEG, senna, lactulose);
             cognitive impairment or inability to document symptoms; known or suspected
             gastrointestinal obstruction or ileus; known or planned pregnancy; no laxative use in
             the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaclyn Y Tran, BScPharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaclyn Y Tran, BScPharm</last_name>
    <phone>902-809-2745</phone>
    <email>jaclyn.tran@nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jo-Anne Wilson, PharmD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Elizabeth Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaclyn Y Tran, BScPharm</last_name>
      <phone>902-473-5025</phone>
      <email>jaclyn.tran@nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jo-Anne Wilson, PharmD</last_name>
      <phone>902-473-5418</phone>
      <email>jo-anne.wilson@nshealth.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.e-therapeutics.ca/search</url>
    <description>Drug monographs for senna, lactulose, and polyethylene glycol</description>
  </link>
  <reference>
    <citation>Mimidis K, Mourvati E, Kaliontzidou M, Papadopoulos V, Thodis E, Kartalis G, Vargemezis V. Efficacy of polyethylene glycol in constipated CAPD patients. Perit Dial Int. 2005 Nov-Dec;25(6):601-3.</citation>
    <PMID>16411529</PMID>
  </reference>
  <reference>
    <citation>Setyapranata S, Holt SG. The Gut in Older Patients on Peritoneal Dialysis. Perit Dial Int. 2015 Nov;35(6):650-4. doi: 10.3747/pdi.2014.00341. Review.</citation>
    <PMID>26702007</PMID>
  </reference>
  <reference>
    <citation>Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001 Nov;96(11):3130-7.</citation>
    <PMID>11721760</PMID>
  </reference>
  <reference>
    <citation>Sutton D, Dumbleton S, Allaway C. Can increased dietary fibre reduce laxative requirement in peritoneal dialysis patients? J Ren Care. 2007 Oct-Dec;33(4):174-8.</citation>
    <PMID>18298035</PMID>
  </reference>
  <reference>
    <citation>Sutton D, Ovington S, Engel B. A multi-centre, randomised trial to assess whether increased dietary fibre intake (using a fibre supplement or high-fibre foods) produces healthy bowel performance and reduces laxative requirement in free living patients on peritoneal dialysis. J Ren Care. 2014 Sep;40(3):157-63. doi: 10.1111/jorc.12056. Epub 2014 Mar 20.</citation>
    <PMID>24650128</PMID>
  </reference>
  <reference>
    <citation>Dessau RB, Olsen OB, Frifelt JJ, Skott H. Influence of psyllium seed husk on azotemia, electrolytes, and bowel regulation in patients on CAPD. Perit Dial Int. 1989;9(4):351.</citation>
    <PMID>2488394</PMID>
  </reference>
  <reference>
    <citation>Pare P. The approach to diagnosis and treatment of chronic constipation: suggestions for a general practitioner. Can J Gastroenterol. 2011 Oct;25 Suppl B:36B-40B.</citation>
    <PMID>22114756</PMID>
  </reference>
  <reference>
    <citation>Liu LW. Chronic constipation: current treatment options. Can J Gastroenterol. 2011 Oct;25 Suppl B:22B-28B. Review.</citation>
    <PMID>22114754</PMID>
  </reference>
  <reference>
    <citation>Schuster BG, Kosar L, Kamrul R. Constipation in older adults: stepwise approach to keep things moving. Can Fam Physician. 2015 Feb;61(2):152-8.</citation>
    <PMID>25676646</PMID>
  </reference>
  <reference>
    <citation>Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005 Apr;100(4):936-71. Review.</citation>
    <PMID>15784043</PMID>
  </reference>
  <reference>
    <citation>Hsieh C. Treatment of constipation in older adults. Am Fam Physician. 2005 Dec 1;72(11):2277-84. Review.</citation>
    <PMID>16342852</PMID>
  </reference>
  <reference>
    <citation>Di Palma JA, Smith JR, Cleveland Mv. Overnight efficacy of polyethylene glycol laxative. Am J Gastroenterol. 2002 Jul;97(7):1776-9.</citation>
    <PMID>12135034</PMID>
  </reference>
  <reference>
    <citation>Attar A, Lémann M, Ferguson A, Halphen M, Boutron MC, Flourié B, Alix E, Salmeron M, Guillemot F, Chaussade S, Ménard AM, Moreau J, Naudin G, Barthet M. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut. 1999 Feb;44(2):226-30.</citation>
    <PMID>9895382</PMID>
  </reference>
  <reference>
    <citation>Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus Polyethylene Glycol for Chronic Constipation. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007570. doi: 10.1002/14651858.CD007570.pub2. Review.</citation>
    <PMID>20614462</PMID>
  </reference>
  <reference>
    <citation>Christie AH, Culbert P, Guest JF. Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics. 2002;20(1):49-60.</citation>
    <PMID>11817992</PMID>
  </reference>
  <reference>
    <citation>Taylor RR, Guest JF. The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering from chronic constipation in the UK. Aliment Pharmacol Ther. 2010 Jan 15;31(2):302-12. doi: 10.1111/j.1365-2036.2009.04191.x. Epub 2009 Nov 3.</citation>
    <PMID>19886948</PMID>
  </reference>
  <reference>
    <citation>Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr;130(5):1480-91. Review. Erratum in: Gastroenterology. 2006 Aug;131(2):688.</citation>
    <PMID>16678561</PMID>
  </reference>
  <reference>
    <citation>Bove A, Pucciani F, Bellini M, Battaglia E, Bocchini R, Altomare DF, Dodi G, Sciaudone G, Falletto E, Piloni V, Gambaccini D, Bove V. Consensus statement AIGO/SICCR: diagnosis and treatment of chronic constipation and obstructed defecation (part I: diagnosis). World J Gastroenterol. 2012 Apr 14;18(14):1555-64. doi: 10.3748/wjg.v18.i14.1555.</citation>
    <PMID>22529683</PMID>
  </reference>
  <reference>
    <citation>Yiannakou Y, Piessevaux H, Bouchoucha M, Schiefke I, Filip R, Gabalec L, Dina I, Stephenson D, Kerstens R, Etherson K, Levine A. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015 May;110(5):741-8. doi: 10.1038/ajg.2015.115. Epub 2015 Apr 14.</citation>
    <PMID>25869393</PMID>
  </reference>
  <reference>
    <citation>Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007 Jul;102(7):1436-41. Epub 2007 Mar 31.</citation>
    <PMID>17403074</PMID>
  </reference>
  <reference>
    <citation>Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005 May;40(5):540-51.</citation>
    <PMID>16036506</PMID>
  </reference>
  <reference>
    <citation>Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999 Sep;34(9):870-7.</citation>
    <PMID>10522604</PMID>
  </reference>
  <reference>
    <citation>Gokal R, Alexander S, Ash S, Chen TW, Danielson A, Holmes C, Joffe P, Moncrief J, Nichols K, Piraino B, Prowant B, Slingeneyer A, Stegmayr B, Twardowski Z, Vas S. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int. 1998 Jan-Feb;18(1):11-33. Review.</citation>
    <PMID>9527026</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>May 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Jaclyn Tran</investigator_full_name>
    <investigator_title>Renal Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

